Cancer
Immunotherapy has revolutionized the treatment of various diseases by harnessing the immune system to combat disease. A new method of delivering monoclonal antibodies, crucial for immunotherapy, is being explored to increase their accessibility and utility. Researchers from GeneOne Life Science Inc. have developed a review highlighting the potential of synthetic
Cancer
Scientists at the Ajou University School of Medicine in South Korea have made a significant discovery in the field of cancer gene therapy. According to their research, published in the International Journal of Stem Cells, the use of antibiotics resistance genes as selection markers can enhance the purity and efficacy
Cancer
Researchers from the University of Central Florida have made a groundbreaking discovery that could potentially lead to a more effective treatment for glioblastomas, a type of aggressive and incurable primary brain tumor. The study, published in the journal Genes, found that suppressing the expression of the NANOG gene in cancer
Cancer
Research conducted by Public Assistance - Paris Hospitals (AP-HP) has shed light on the potential benefits of timing immune checkpoint inhibitors (ICIs) in the treatment of metastatic cancer. The study, published in the Journal of Clinical Oncology, suggests that administering ICIs in the morning or early part of the day
Cancer
Cancer Weekly has reported on the groundbreaking research conducted by investigators at Imperial College London, which has yielded promising results for IMM60, a novel iNKT agonist formulated in a liposome. The study, IMPORT-201 (IMP-MEL), has demonstrated that IMM60 is well-tolerated as monotherapy and in combination with pembrolizumab in a heavily
Cancer
The U.S. Department of Defense, Assistive Technology Research and Applications Agency (AMRAA) has issued a grants notice, titled "DoD Kidney Cancer, Nurse Initiated Research Award", which aims to fund innovative, high-impact kidney cancer research conducted by nurses working in clinical practice and/or an academic environment. The
Cancer
The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. The market is driven by the high specificity, discernment, small sizes,
Cancer
Research on hepatocellular carcinoma (HCC) has identified a novel prognostic model that utilizes genes related to DNA damage response (DDR) to predict patient outcomes. The study, which utilized a dataset of 238 patients, found that patients with lower risk scores demonstrated better survival rates compared to those with higher risk
Cancer
Researchers at Monash University Malaysia have made a groundbreaking discovery in the field of cancer gene therapy, utilizing Phage N15-based vectors for gene cloning and expression in both bacterial and mammalian cells. This cutting-edge technology has shown remarkable cloning fidelity in propagating unstable repetitive DNA sequences and large genomic fragments,
Cancer
Research from Kaiser Permanente Los Angeles Medical Center has shed light on the treatment of POLE-mutant colon cancer, a condition characterized by high tumor mutational burden and a high response rate to immunotherapy. The study found that treatment with pembrolizumab, a PD-1 blocker, led to the clearance of circulating tumor
Cancer
Cancer remains a major global health challenge, affecting millions worldwide. Researchers at Kumoh National Institute of Technology in Gumi, South Korea, have been working on developing alternative treatment strategies to traditional chemotherapy, including gene therapy. Their research focuses on using mesoporous silica nanoparticles (MSNs) as a gene delivery platform for
Cancer
Researchers at Southern Medical University have made significant progress in cancer gene therapy using CD19 chimeric antigen receptor (CAR) engineered NK cells. In a study published in Frontiers in Immunology, the team demonstrated enhanced responses against B cell malignancies with CD19 CAR engineered memory-like NK cells. These findings have the
